Skip to main content
SpringerLink
Log in

Cost effectiveness of long-acting risperidone: What can pharmacoeconomic models teach us?

  • Introduction
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Knapp M. Costs of schizophrenia. Br J Psychiatry 1997; 171: 509–18

    Article  PubMed  CAS  Google Scholar 

  2. Davies L, Drummond M. The economic burden of schizophrenia. Psychiatr Bull 1990; 14: 522–5

    Article  Google Scholar 

  3. Terkelsen KG, Menikoff A. Measuring the costs of schizophrenia. Implications for the post-institutional era in the US. PharmacoEconomics 1995; 8: 199–222

    Article  PubMed  CAS  Google Scholar 

  4. Ettaro L, Songer TJ, Zhang P, et al. Cost-of-illness studies in diabetes mellitus. PharmacoEconomics 2004; 22: 149–64

    Article  PubMed  Google Scholar 

  5. Wyatt RJ, Henter I, Leary MC, et al. An economic evaluation of schizophrenia — 1991. Soc Psychiatry Psychiatr Epidemiol 1995; 30: 196–205

    PubMed  CAS  Google Scholar 

  6. Almond S, Knapp M, Francois C, et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004; 184: 346–51

    Article  PubMed  Google Scholar 

  7. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21: 419–29

    Article  PubMed  CAS  Google Scholar 

  8. Barnes TR, Curson DA. Long-term depot antipsychotics. A risk—benefit assessment. Drug Safety 1994; 10: 464–79

    Article  PubMed  CAS  Google Scholar 

  9. Brown CS, Markowitz JS, Moore TR, et al. Atypical antipsychotics: part II: Adverse effects, drug interactions, and costs. Ann Pharmacother 1999; 33: 210–7

    Article  PubMed  CAS  Google Scholar 

  10. Buxton MJ, Drummond MF, van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Economics 1997; 6: 217–27

    Article  PubMed  CAS  Google Scholar 

  11. Haycox A. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. PharmacoEconomics 2005; 23 (Suppl. 1): 3–16

    PubMed  CAS  Google Scholar 

  12. Heeg BMS, Buskens E, Knapp M, et al. Modelling the treated course of schizophrenia: development of a discrete event simulation model. PharmacoEconomics 2005; 23 (Suppl. 1): 17–33

    Google Scholar 

  13. De Graeve D, Smet A, Mehnert A, et al. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. PharmacoEconomics 2005; 23 (Suppl. 1): 35–47

    PubMed  Google Scholar 

  14. Laux G, Heeg BMS, van Hout BA, et al. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. PharmacoEconomics 2005; 23 (Suppl. 1): 49–61

    Google Scholar 

  15. Chue PS, Heeg BMS, Buskens E, et al. Modelling the impact of compliance on the costs and effects of longacting risperidone in Canada. PharmacoEconomics 2005; 23 (Suppl. 1): 62–74

    PubMed  Google Scholar 

  16. Edwards NC, Locklear JC, Rupnow MFT, et al. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. PharmacoEconomics 2005; 23 (Suppl. 1): 75–89

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Public Health, Ghent University, and HEDM, IMS Health, Brussels, Belgium

    Lieven Annemans

Authors
  1. Lieven Annemans
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lieven Annemans.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Annemans, L. Cost effectiveness of long-acting risperidone: What can pharmacoeconomic models teach us?. Pharmacoeconomics 23 (Suppl 1), 1–2 (2005). https://doi.org/10.2165/00019053-200523001-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200523001-00001

Keywords

Search

Navigation